469 related articles for article (PubMed ID: 2972431)
1. Endocrine effects of combined treatment with an LHRH agonist in association with flutamide in metastatic prostatic carcinoma.
Bélanger A; Labrie F; Dupont A; Brochu M; Cusan L
Clin Invest Med; 1988 Oct; 11(5):321-6. PubMed ID: 2972431
[TBL] [Abstract][Full Text] [Related]
2. Stimulation of the circulating levels of glycoprotein hormone alpha-subunit after combined administration of a luteinizing hormone-releasing hormone (LHRH) agonist and flutamide in patients with cancer of the prostate.
St-Arnaud R; Lachance R; Dupont A; Labrie F
Clin Invest Med; 1986 Nov; 9(4):215-21. PubMed ID: 2433088
[TBL] [Abstract][Full Text] [Related]
3. The rise in testicular androgens during the first days of treatment with an LHRH agonist in the dog can be blocked by aminoglutethimide or ketoconazole.
Lacoste D; St-Arnaud R; Caron S; Belanger A; Labrie F
J Steroid Biochem; 1988 Dec; 31(6):963-70. PubMed ID: 3059065
[TBL] [Abstract][Full Text] [Related]
4. Effect of 3-week treatment with [D-Trp6, des-Gly-NH10(2)]LHRH ethylamide, aminoglutethimide, ketoconazole or flutamide alone or in combination on testicular, serum, adrenal and prostatic steroid levels in the dog.
Lacoste D; Caron S; Bélanger A; Labrie F
J Steroid Biochem; 1989 Aug; 33(2):233-42. PubMed ID: 2671505
[TBL] [Abstract][Full Text] [Related]
5. Characteristics of flutamide action on prostatic and testicular functions in the rat.
Marchetti B; Labrie F
J Steroid Biochem; 1988 Jun; 29(6):691-8. PubMed ID: 2838689
[TBL] [Abstract][Full Text] [Related]
6. [Change of serum adrenal androgens in prostatic cancer patients after bilateral orchidectomy or LHRH agonist treatment].
Oka H; Negoro H; Sugino Y; Iwamura H; Moroi S; Kawakita M
Hinyokika Kiyo; 2003 Sep; 49(9):521-5. PubMed ID: 14598689
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancer.
Labrie F; Dupont A; Giguère M; Borsanyi JP; Lacourciere Y; Bélanger A; Lachance R; Emond J; Monfette G
Prog Clin Biol Res; 1988; 260():41-62. PubMed ID: 3283766
[TBL] [Abstract][Full Text] [Related]
8. Loss of luteinizing hormone bioactivity in patients with prostatic cancer treated with an LHRH agonist and a pure antiandrogen.
St-Arnaud R; Lachance R; Kelly SJ; Belanger A; Dupont A; Labrie F
Clin Endocrinol (Oxf); 1986 Jan; 24(1):21-30. PubMed ID: 3519004
[TBL] [Abstract][Full Text] [Related]
9. Intermittent long-term administration of a potent gonadotropin-releasing hormone agonist in normal men.
Doelle G; Linde R; Alexander N; Kirchner F; Vale W; Rivier J; Rabin D
Int J Fertil; 1982; 27(4):234-7. PubMed ID: 6131043
[TBL] [Abstract][Full Text] [Related]
10. Effects of flutamide and aminoglutethimide on plasma 5 alpha-reduced steroid glucuronide concentrations in castrated patients with cancer of the prostate.
Brochu M; Bélanger A; Dupont A; Cusan L; Labrie F
J Steroid Biochem; 1987 Dec; 28(6):619-22. PubMed ID: 2961945
[TBL] [Abstract][Full Text] [Related]
11. Effect of 2-week combination therapy with the luteinizing hormone-releasing hormone (LHRH) agonist [D-Trp6, des-Gly-NH2(10)]LHRH ethylamide and the antiandrogen flutamide on prostate structure and steroid levels in the dog.
Lacoste D; Dubé D; Bélanger A; Labrie F
Mol Cell Endocrinol; 1989 Dec; 67(2-3):131-8. PubMed ID: 2693158
[TBL] [Abstract][Full Text] [Related]
12. Complete response to combination therapy with an LHRH agonist and flutamide in metastatic male breast cancer: a case report.
Labrie F; Dupont A; Bélanger A; Lacourcière Y; Béland L; Cusan L; Lachance R
Clin Invest Med; 1990 Oct; 13(5):275-8. PubMed ID: 2276222
[TBL] [Abstract][Full Text] [Related]
13. Long-term effects of endocrine treatment on serum steroids in advanced prostatic carcinoma patients.
Lukkarinen O; Hammond GL; Kontturi M; Vihko R
Invest Urol; 1980 Jan; 17(4):328-31. PubMed ID: 6444293
[TBL] [Abstract][Full Text] [Related]
14. Partial androgen suppression consequent to increased secretion of adrenal androgens in a patient with prostate cancer treated with long-acting GnRH agonists.
Spitz IM; Chertin B; Fridmans A; Farkas A; Belanger A; Hartman H; Labrie F
Prostate Cancer Prostatic Dis; 2009; 12(1):100-3. PubMed ID: 18574491
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy with flutamide and [D-Trp6, des-Gly-NH2(10)]LHRH ethylamide in stage C and D prostate cancer: today's therapy of choice--rationale and 5-year clinical experience.
Labrie F; Dupont A; Cusan L; Bélanger A; Giguère M; Labrie C; Lacourcière Y; Monfette G; Emond J
Prog Clin Biol Res; 1988; 262():11-63. PubMed ID: 3287388
[No Abstract] [Full Text] [Related]
16. Serum luteinizing hormone (LH) biological activity in castrated patients with cancer of the prostate receiving a pure antiandrogen and in estrogen-pretreated patients treated with an LH-releasing hormone agonist and antiandrogen.
St Arnaud R; Lachance R; Dupont A; Labrie F
J Clin Endocrinol Metab; 1986 Aug; 63(2):297-302. PubMed ID: 3522618
[TBL] [Abstract][Full Text] [Related]
17. Androgen level variations, clinical response to LHRH agonists and changes in the quality of life subscales in metastatic prostate cancer--speculations about possible role of the monoamine system.
Popov I; Jelić S; Radosavljević D; Nikolić-Tomasević Z
Neoplasma; 1997; 44(5):308-13. PubMed ID: 9473791
[TBL] [Abstract][Full Text] [Related]
18. Serum levels of follicle stimulating hormone, luteinizing hormone, prolactin, testosterone, 5 alpha-dihydrotestosterone, 5 alpha-androstane-3 alpha, 17 beta-diol, 5 alpha-androstane-3 beta, 17 beta-diol, and 17 beta-estradiol from male beagles with spontaneous or induced benign prostatic hyperplasia.
Cochran RC; Ewing LL; Niswender GD
Invest Urol; 1981 Nov; 19(3):142-7. PubMed ID: 6170603
[TBL] [Abstract][Full Text] [Related]
19. New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen.
Labrie F; Dupont A; Belanger A; Cusan L; Lacourciere Y; Monfette G; Laberge JG; Emond JP; Fazekas AT; Raynaud JP; Husson JM
Clin Invest Med; 1982; 5(4):267-75. PubMed ID: 6819101
[TBL] [Abstract][Full Text] [Related]
20. Major advantages of "early" administration of endocrine combination therapy in advanced prostate cancer.
Labrie F; Dupont A; Cusan L; Gomez JL; Diamond P
Clin Invest Med; 1993 Dec; 16(6):493-8. PubMed ID: 8013154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
